MARKET

IMA

IMA

ImageneBio
NASDAQ
6.91
+0.06
+0.88%
After Hours: 6.91 0 0.00% 16:10 02/13 EST
OPEN
6.95
PREV CLOSE
6.85
HIGH
7.21
LOW
6.87
VOLUME
18.47K
TURNOVER
--
52 WEEK HIGH
19.20
52 WEEK LOW
5.70
MARKET CAP
77.27M
P/E (TTM)
-0.8525
1D
5D
1M
3M
1Y
5Y
1D
Vanguard Total Stock Market ETF (VTI) Daily Update—2/13/26
TipRanks · 12h ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/12/26
TipRanks · 1d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/11/26
TipRanks · 2d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/10/26
TipRanks · 3d ago
ImageneBio appoints Ben Porter-Brown as Chief Medical Officer
TipRanks · 3d ago
*ImageneBio Appoints Ben Porter-Brown as Chief Medical Officer >IMA
Dow Jones · 3d ago
ImageneBio Names Dr. Ben Porter-Brown as Chief Medical Officer
Reuters · 3d ago
Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
Dow Jones · 3d ago
More
About IMA
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

Webull offers ImageneBio Inc stock information, including NASDAQ: IMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMA stock methods without spending real money on the virtual paper trading platform.